Phase 2 trial in 76 patients with large duct primary sclerosing cholangitis: nebokitug 10 or 20 mg/kg had adverse events similar to placebo; liver tests, ELF and liver stiffness did not change overall at 15 weeks, but stiffness fell in 35 with moderate/advanced fibrosis.
RCTn = 76
Bowlus et al. Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study